Primary Outcome Measures Disease control [ Time Frame: 12 weeks ] Disease control rate at 12 weeks Secondary Outcome Measures Survival with anti-PD1/PDL1 immunotherapy [ Time Frame: 12 weeks ] Overall survival from treatment with anti-PD1/PDL1 immunotherapy Duration of treatment [ Time Frame: 12 weeks ] Duration of treatment with PD1/PDL1 immunotherapy Survival [ Time Frame: 12 weeks ] Overall survival from the start of the[…]
Closed
Intravenous Magnesium in Patients Receiving Cisplatin
Primary Outcome Measures Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ] Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time[…]
Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
Primary Outcome Measures Local tumor infiltration by cytotoxic cluster of differentiation 8 positive (CD8+) cells [ Time Frame: After cryoablation of mesothelioma up to 1 year ] Will be tested by cryoablating a small region of tumor at the time of pleural biopsy. Preponderance of T cells in ablated tumor tissue in comparison to[…]
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.
Confocal Laser Endomicroscopy in Pleural Malignancies
Purpose:To date, the different biopsy methods, such as CT-guided pleural biopsy, mediastinal biopsy, endosonography and thoracoscopy have their limitations in diagnosing pleural malignancies, such as mesothelioma. Sampling errors frequently occur resulting in the common histological finding of ‘non-specific pleuritic/fibrosis’, which presents a great uncertainty for clinicians and patients. Confocal laser endomicroscopy (CLE) provides real-time imaging on a cellular level, however data of CLE in pleural malignancies are lacking.
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Purpose:The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Purpose: This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Purpose: his research study is studying a pair of immunotherapies as a possible treatment for malignant pleural mesothelioma. The drugs involved in this study are Durvalumab and Tremelimumab.
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
Purpose: To estimate the time to progression of cancer in patients with previously untreated mesothelioma receiving cisplatin, pemetrexed and bevacizumab
